Analyst Price Targets — NVAX
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| October 24, 2025 11:45 am | — | Cantor Fitzgerald | $18.00 | $8.55 | TheFly | Novavax initiated with an Overweight at Cantor Fitzgerald |
| October 23, 2025 12:20 pm | Sean Lee | H.C. Wainwright | $11.00 | $8.46 | TheFly | Novavax price target raised to $11 from $10 at H.C. Wainwright |
| November 18, 2024 12:39 pm | Mayank Mamtani | B.Riley Financial | $22.00 | $7.58 | StreetInsider | Novavax (NVAX) PT Lowered to $22 at B.Riley |
| October 16, 2024 1:29 pm | Roger Song | Jefferies | $25.00 | $10.15 | StreetInsider | Novavax (NVAX) PT Lowered to $25 at Jefferies |
| October 16, 2024 11:43 am | Alec Stranahan | Bank of America Securities | $14.00 | $10.45 | StreetInsider | Novavax (NVAX) PT Lowered to $14 at BofA Securities 'to reflect delays in phase 3 CIC/standalone flu trial' |
| July 19, 2024 11:37 am | Roger Song | Jefferies | $31.00 | $14.36 | TheFly | Novavax price target lowered to $31 from $38 at Jefferies |
| May 10, 2024 10:56 am | Vernon Bernardino | H.C. Wainwright | $19.00 | $9.94 | TheFly | H.C. Wainwright reiterates Buy rating on Novavax after 'landmark' Sanofi deal |
| February 14, 2022 12:00 am | Charles Duncan | Cantor Fitzgerald | $174.00 | $80.11 | Pulse 2.0 | Novavax (NVAX) Stock: $174 Price Target From Cantor Fitzgerald |
Latest News for NVAX
Novavax Inc. (NASDAQ: NVAX) shares are down on Friday, possibly on profit-taking after the stock rallied on Thursday following the company's announcement of its fourth-quarter and full-year 2025 financial results.
Novavax (NVAX) has transitioned into a royalty-driven model, with Q4 profitability and 73% of revenue from licensing and royalties. NVAX's FY26 revenue guidance of $230M–$270M reflects cleaner, high-margin cash flow, excluding potential $200M in milestones from Sanofi. With $857M in cash and receivables, NVAX is funded into 2028, but remains highly dependent on partner outcomes, especially Sanofi's COVID/influenza…
NVAX stock jumps 17% after Q4 swings to a surprise profit on strong licensing revenues and lower costs, with sales soaring 67% year over year.
GAITHERSBURG, Md., Feb. 26, 2026 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), today announced that it will participate in the following upcoming investor conferences: TD Cowen 46 th Annual Health Care Conference: Fireside Chat Date: Tuesday, March 3, 2026 Time: 2:30 p.m.
Novavax, Inc. (NVAX) Q4 2025 Earnings Call Transcript
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
Senate Trading Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
U.S. House Trading
No House trades found for NVAX.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.